FCER1G activation to create TREM2-bypass immune signaling through alternative receptor pathways
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["TREM2 Loss-of-Function R47H Variant or Shedding"]
B["Microglial Phagocytic Deficit Amyloid Debris Accumulation"]
C["FCER1G FcRgamma Expression Alternative Innate Immune Receptor"]
D["FCER1G Activation IgG-Opsonized Substrate Binding"]
E["ITAM Signaling via FcRgamma SYK LYN Kinase Activation"]
F["Bypass of TREM2-TYROBP Alternative DAP10/DAP12 Axis"]
G["Phagocytosis Restored TREM2-Independent Clearance"]
H["Amyloid Plaque Burden Reduced Microglial Function Preserved"]
A --> B
B -.->|"impaired clearance"| H
C --> D
D --> E
E --> F
F --> G
G --> H
style F fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style H fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
6 citations6 with PMID5 mediumValidation: 40%5 supporting / 1 opposing
✓For(5)
5
No opposing evidence
(1)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
3
3
MECH 3CLIN 0GENE 3EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
TREM2 macrophage promotes cardiac repair in myocar…
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-06 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Based on the information gathered about TREM2, its protein interactions, and pathways, I'll now generate novel therapeutic hypotheses for targeting TREM2 in Alzheimer's disease following the INVOKE-2 failure:
Novel Therapeutic Hypotheses for TREM2 in Alzheimer's Disease
Hypothesis 1: TYROBP-SYK Pathway Enhancement
Title: Selective TYROBP stabilization to bypass TREM2 ectodomain loss
Description: Given TREM2's obligate partnership with TYROBP (DAP12) for signaling, developing small molecule stabilizers of the TYROBP-SYK complex could maintain downstream neuroprotective signali
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
I'll critically evaluate each of these TREM2 therapeutic hypotheses by examining their weaknesses, counter-evidence, and proposing falsifying experiments.
Critical Evaluation of TREM2 Therapeutic Hypotheses
Hypothesis 1: TYROBP-SYK Pathway Enhancement
Specific Weaknesses:
Assumes TYROBP-SYK signaling is universally beneficial, ignoring potential inflammatory consequences
Overlooks that TYROBP is shared with multiple immune receptors (not TREM2-specific)
No consideration of dose-response relationships or therapeutic window
Counter-evidence: The literature shows that exce
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Based on my analysis of the therapeutic hypotheses and available clinical data, here's my practical feasibility assessment:
PRACTICAL FEASIBILITY ASSESSMENT
HYPOTHESIS 1: TYROBP-SYK PATHWAY ENHANCEMENT
Druggability: MODERATE
Existing compounds: Fostamatinib (SYK inhibitor, FDA-approved for ITP)
Chemical matter: Multiple SYK inhibitors exist (fostamatinib, entospletinib, TAK-659)
Target validation: Strong - SYK is highly druggable kinase with validated inhibitors
Competitive Landscape:
Rigel Pharmaceuticals (fostamatinib) - established SYK franchise
M
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
Based on the comprehensive debate between the Theorist, Skeptic, and Expert, I'll synthesize their inputs and produce final scored rankings. Let me analyze the evidence and score each hypothesis across the 10 dimensions.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
💬 Discussion
Loading comments...
No DepMap CRISPR Chronos data found for ['FCER1G'].
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
IF FCER1G is genetically silenced (siRNA) in human macrophage cell lines, THEN phospho-SYK and phospho-SLP-65 signaling pathway activation will decrease by >50% compared to control cells within 48 hours using RAW 264.7 murine macrophages and human THP-1 monocyte-derived macrophages.
pendingconf: 0.72
Expected outcome: FCER1G knockdown will significantly reduce downstream ITAM pathway activation markers (phospho-SYK, phospho-BLAT, phospho-ERK1/2) while baseline NF-κB activity remains unchanged, demonstrating FCER1G's role as a critical adaptor in alternative immune receptor signaling cascades independent of canonical TREM2 pathways.
Falsified by: If FCER1G knockdown produces no significant change (<20% variation) in SYK/SLP-65 phosphorylation levels, the hypothesis that FCER1G mediates alternative immune signaling through ITAM-dependent pathways would be falsified.
Method: Transfect macrophages with FCER1G-specific siRNA or non-targeting control siRNA. After 48 hours, stimulate cells with FcεRI crosslinking or immune receptor ligands. Harvest cell lysates for phospho-flow cytometry and Western blot analysis of SYK, SLP-65, BLAT, and ERK1/2 activation markers. Quantify using densitometry and compare fold-changes between knockdown and control conditions.
IF TREM2 is pharmacologically inhibited (anti-TREM2 blocking antibody) AND FCER1G is simultaneously overexpressed via plasmid transfection in microglia-like cells, THEN phagocytic activity and inflammatory cytokine production (IL-6, TNF-α) will remain at baseline levels within 72 hours using BV-2 microglial cells or iPSC-derived human microglia.
pendingconf: 0.68
Expected outcome: TREM2 blockade alone will reduce phagocytosis by ~40-60% and alter cytokine profiles, but co-overexpression of FCER1G will rescue these functional deficits, restoring phagocytic index to >80% of untreated control levels and normalizing cytokine secretion patterns, indicating FCER1G can functionally bypass TREM2-mediated signaling.
Falsified by: If TREM2 inhibition causes >60% reduction in phagocytic activity AND FCER1G overexpression fails to rescue this defect (remains <50% of baseline), the hypothesis that FCER1G creates TREM2-bypass alternative signaling would be disproven.
Method: Transfect BV-2 cells or iPSC-derived microglia with FCER1G overexpression plasmid or empty vector control. After 24 hours, treat cells with TREM2-blocking antibody (10 μg/mL) for 48 hours. Perform phagocytosis assay using pHrodo-labeled E. coli particles. Measure IL-6 and TNF-α secretion via ELISA. Analyze via flow cytometry to quantify phagocytic index and cytokine levels. Include positive controls (TREM2 agonist), negative controls (vector-only), and experimental conditions.
Knowledge Subgraph (0 edges)
No knowledge graph edges recorded
3D Protein Structure
🧬
['FCER1G'] — Search for structure
Click to search RCSB PDB